Exclusive Summary

• • Trageting ECD2/4, promising data readout at ASCO 2025 (HR+BC) and WCLC 2025 (NSCLC), with potential better performance at HER low+indication and better safety profile( RP2D dose ORR 58.33% DCR 86.11%) . Rare Interstitial lung diseases were reported.
• • Favorable competitive landscape for Bioparotopic Her2 ADC.